Physiomics plc announced that it has been awarded a substantial new contract by an existing large pharma client. The project involves Pharmacokinetic-Pharmacodynamic (PKPD) modelling in the field of DNA damage/repair field and will help inform clinical dose and scheduling decisions. The value of the project is £178,000 and it is anticipated that it will be completed over the course of the next six months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.3 GBX | -.--% | -.--% | -18.75% |
Jun. 01 | EXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood Tech | AN |
May. 31 | Physiomics Chief Scientist Steps Down | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.75% | 2.24M | |
+21.07% | 77.46B | |
-12.46% | 39.23B | |
+13.48% | 37.74B | |
-6.43% | 28.6B | |
-15.26% | 15.41B | |
+4.67% | 13.97B | |
+9.96% | 10.44B | |
-18.03% | 4.25B | |
-38.44% | 3.81B |
- Stock Market
- Equities
- PYC Stock
- News Physiomics Plc
- Physiomics plc Wins Contract by an Existing Pharma Client